UCB (EQUASYM worldwide rights) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

UCB (EQUASYM worldwide rights) General Information

Description

Portfolio of pharmaceutical rights and patents. The portfolio entails worldwide rights to the instant-release and extended-release versions of Equasym outside the United States, Canada and Barbados. Equasym IR and XL are used for the treatment of attention deficit hyperactivity disorder (ADD).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Business Products and Services
Other Healthcare
Acquirer
Primary Office
  • Brussels
  • Belgium
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

UCB (EQUASYM worldwide rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore UCB (EQUASYM worldwide rights)‘s full profile, request access.

Request a free trial

UCB (EQUASYM worldwide rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore UCB (EQUASYM worldwide rights)‘s full profile, request access.

Request a free trial